Tags : Non-Core Assets

Takeda to Divest a Portfolio of Select OTC and Non-Core

Shots: Takeda will divest a portfolio of ~18 select OTC and prescription pharmaceutical assets including Neosaldina, Nesina, and Dramin sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru to Hypera for a total value ~$825M. The transaction is expected to be close in H2’20 Takeda expects that its ~300 employees supporting the divested assets […]Read More

Takeda to Divest its Portfolio of Select OTC and Non-Core

Shots: Takeda to receive ~$660M for divesting its 20 select prescription pharmaceutical and OTC products traded in Russia, Georgia, and several countries within the Commonwealth of Independent States. STADA to get rights, title, and interest to the products in the portfolio exclusive in these countries. The transaction is expected to close in Q4’19 Additionally, Takeda […]Read More

Takeda to Divest its Portfolio of Select OTC and Non-Core

Shots: Takeda to receive ~$200M for divesting its 30 select prescription pharmaceutical and OTC products traded in Near East, Middle East and Africa (NEMEA) countries. Acino to get rights, title, and interest to the products in the portfolio exclusive in NEMEA. The transaction is expected to close in Q4’19 Additionally, Takeda and Acino will sign […]Read More